Therapeutic advance: A comparison of assessments made by Prescrire and by the Swedish regulatory agency

Prescrire International

Volumn 14, Issue 80, 2005, Pages 236-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; CLOPIDOGREL; DESULFATOHIRUDIN; GEMCITABINE; IMIQUIMOD; NALTREXONE; NARATRIPTAN; PENCICLOVIR; SUMATRIPTAN; TICLOPIDINE;

ACCESS TO INFORMATION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURAL FACTOR; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG INDUSTRY; DRUG MARKETING; FRANCE; HEALTH CARE ORGANIZATION; HERPES; HUMAN; MIGRAINE; PHLEBOGRAPHY; RISK BENEFIT ANALYSIS; SWEDEN; VEIN THROMBOSIS;

EID: 28644442985     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. International Society of Drug Bulletins "ISDB Declaration on therapeutic advance in the use of medicines" available on www.isdbweb.org
2. Prescrire Editorial Staff "Comparaive advantages of new drugs: French authorities are not sufficiently demanding" Prescrire Int 2005; 14 (76): 75-76.
3. Ahlqvist-Rastad J et al. "Judging the therapeutic value of drugs: a comparison between La revue Prescrire and Information från Läkemedelsverket, the bulletin of the Swedish Medical Products Agency" International Journal of Risk & Safety in Medicine 2004; 16: 83-90.
4. Rosén A and Beermann B "Rating innovative therapeutic benefits of medicines licensed in Sweden 1987-1997" Int J Pharma Med 1999; 13 (3): 123-126.